7 completed. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
Follow Fibromyalgia Syndrome: new trials by email Literature Review of Fibromyalgia Syndrome trials Research Report on Fibromyalgia Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Post-Traumatic Stress Disorder Treatment by Reconsolidation Therapy on Fibromyalgia Syndrome Propranolol - Fibromyalgia Syndrome, Posttraumatic Stress Disorder | Phase 2 | Completed | Centre Hospitalier Henri Laborit | 17 | 2021-08-13 | 2026-09-09 |
| Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments 5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream - Vestibulodynia, Temporomandibular Disorder | Phase 2 | Completed | Duke University | 209 | 2019-11-04 | 2026-03-19 |
| Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome mirtazapine, placebo - Fibromyalgia Syndrome | Phase 2 | Completed | Mahidol University | 80 | 2008-12-01 | 2012-07-25 |
| The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. Rotigotine, Placebo - Fibromyalgia Syndrome | Phase 2 | Completed | UCB Pharma | 230 | 2007-03-01 | 2015-06-22 |
| Efficacy of S-Adenosylmethionine in Fibromyalgia SAM-e (S-Adenosyl-L-Methionine) - Fibromyalgia Syndrome | Phase 2 | Completed | Deakin University | 70 | 2006-11-01 | 2007-09-12 |
| Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome. Lacosamide, Placebo - Fibromyalgia Syndrome | Phase 2 | Completed | UCB Pharma | 159 | 2006-10-01 | 2018-07-18 |
| Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran Milnacipran, Placebo - Fibromyalgia Syndrome | Phase 2 | Completed | Pierre Fabre Medicament | 153 | 2006-09-01 | 2013-07-11 |
Fibromyalgia (7) · Back Pain (1) · Chronic Pain (1) · Cystitis, Interstitial (1) · Endometriosis (1) · Fatigue Syndrome, Chronic (1) · Irritable Bowel Syndrome (1) · Migraine Disorders (1) · Pelvic Pain (1) · Stress Disorders, Post-Traumatic (1) · Temporomandibular Joint Disorders (1) · Tension-Type Headache (1) · Vulvodynia (1)
Muscular Diseases (7) · Musculoskeletal Diseases (7) · Nervous System Diseases (7) · Neuromuscular Diseases (7) · Rheumatic Diseases (7) · Brain Diseases (1) · Central Nervous System Diseases (1) · Chronic Disease (1) · Colonic Diseases (1) · Colonic Diseases, Functional (1) · Craniomandibular Disorders (1) · Cystitis (1) · Digestive System Diseases (1) · Disease Attributes (1) · Encephalomyelitis (1)
2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)- (1) · Lacosamide (1) · Milnacipran (1) · Mirtazapine (1) · Nortriptyline (1) · Propranolol (1) · S-Adenosylmethionine (1) · rotigotine (1)
UCB Pharma (2) · Centre Hospitalier Henri Laborit (1) · Deakin University (1) · Duke University (1) · Mahidol University (1) · Pierre Fabre Medicament (1)
United States (3) · Australia (1) · France (1) · Switzerland (1) · Thailand (1)
Andrea Nackley, PhD (1) · Gregory A Tooley, PhD (1) · Jules Desmeules, MD (1) · Nematollah Jaafari, Professor (1) · Saithip Suttiruksa, Master (1) · Suwimon Yeephu (1)
PMID 36269028, PMID 41595724, PMID 42857927
R01HD096331 (1)